US20130184268A1 - 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl) propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof - Google Patents

2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl) propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof Download PDF

Info

Publication number
US20130184268A1
US20130184268A1 US13/821,515 US201113821515A US2013184268A1 US 20130184268 A1 US20130184268 A1 US 20130184268A1 US 201113821515 A US201113821515 A US 201113821515A US 2013184268 A1 US2013184268 A1 US 2013184268A1
Authority
US
United States
Prior art keywords
amyloidopathy
group
piperazin
thio
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/821,515
Other languages
English (en)
Inventor
Jens Pahnke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immungenetics AG
Original Assignee
Immungenetics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immungenetics AG filed Critical Immungenetics AG
Assigned to IMMUNGENETICS AG reassignment IMMUNGENETICS AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PAHNKE, JENS
Publication of US20130184268A1 publication Critical patent/US20130184268A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
    • C07D279/18—[b, e]-condensed with two six-membered rings
    • C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
    • C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
US13/821,515 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl) propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof Abandoned US20130184268A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102010044561 2010-09-07
DE102010044561.4 2010-09-07
PCT/EP2011/064893 WO2012031941A2 (de) 2010-09-07 2011-08-30 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/064893 A-371-Of-International WO2012031941A2 (de) 2010-09-07 2011-08-30 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/499,918 Division US9370523B2 (en) 2010-09-07 2014-09-29 Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
US14/847,089 Division US20150374711A1 (en) 2010-09-07 2015-09-08 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazines for treating a b-amyloidopathy or an a-synucleopathy, and method for the diagnosis or prediagnosis thereof

Publications (1)

Publication Number Publication Date
US20130184268A1 true US20130184268A1 (en) 2013-07-18

Family

ID=44645670

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/821,515 Abandoned US20130184268A1 (en) 2010-09-07 2011-08-30 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl) propyl]-10h-phenothiazine for treating a beta-amyloidopathy or an alpha-synucleopathy, and method for the diagnosis or prediagnosis thereof
US14/499,918 Active 2031-09-30 US9370523B2 (en) 2010-09-07 2014-09-29 Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
US14/847,089 Abandoned US20150374711A1 (en) 2010-09-07 2015-09-08 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazines for treating a b-amyloidopathy or an a-synucleopathy, and method for the diagnosis or prediagnosis thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/499,918 Active 2031-09-30 US9370523B2 (en) 2010-09-07 2014-09-29 Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
US14/847,089 Abandoned US20150374711A1 (en) 2010-09-07 2015-09-08 2-(r2-thio)-10-[3-(4-r1-piperazin-1-yl)propyl]-10h-phenothiazines for treating a b-amyloidopathy or an a-synucleopathy, and method for the diagnosis or prediagnosis thereof

Country Status (13)

Country Link
US (3) US20130184268A1 (de)
EP (3) EP2614060B1 (de)
JP (2) JP6084924B2 (de)
CN (2) CN106243060A (de)
BR (1) BR112013005472A2 (de)
CA (2) CA2811454C (de)
DE (2) DE102010062810B4 (de)
DK (2) DK2614060T3 (de)
ES (2) ES2701453T3 (de)
MX (1) MX357521B (de)
PL (2) PL2693216T3 (de)
RU (2) RU2587154C2 (de)
WO (1) WO2012031941A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023131606A1 (en) * 2022-01-04 2023-07-13 Immungenetics Ag Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia
WO2024083822A1 (en) * 2022-10-18 2024-04-25 Immungenetics Ag Identifying a subject suffering from alzheimer's dementia or being at risk of developing alzheimer's dementia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298852A1 (en) * 2005-03-23 2009-12-03 Gernot Francas Pellet-form slow-release preparation for vertigo

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH365379A (de) * 1956-04-18 1962-11-15 Sandoz Ag Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen
BE568701A (de) * 1957-06-18
US3621097A (en) * 1970-03-30 1971-11-16 Jan Marcel Didier Aron Samuel Method and compositions for treatment of mental illness
US4471116A (en) * 1982-07-28 1984-09-11 Hoffmann-La Roche Inc. Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines
US6566368B2 (en) * 1994-04-22 2003-05-20 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage form for ameliorating male erectile dysfunction
CA2196529A1 (en) * 1994-08-08 1996-02-22 Peter Davies Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes
DE4430091A1 (de) * 1994-08-25 1996-02-29 Bayer Ag Verwendung von N-substituierten Phenothiazinen
EP1470818B1 (de) * 2003-04-25 2006-07-26 Neuro3D Verwendung von Piperazin- Phenothiazin- Derivaten zur Herstellung eines Arzneimittels mit neuroprotektiven und/oder neurotropischen Wirkungen auf das ZNS und/oder PNS
WO2007062862A2 (en) * 2005-12-02 2007-06-07 Ludwig Maximilians Universität München Use of calmodulin inhibitors for the treatment of neurodegenerative disorders
CN101511803B (zh) * 2006-07-11 2012-10-31 维斯塔实验室有限公司 二氨基吩噻嗪*化合物的合成和/或纯化方法
WO2008057608A2 (en) * 2006-11-10 2008-05-15 Cara Therapeutics, Inc. Synthetic peptide amides
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
WO2008133884A2 (en) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
CN102065897B (zh) * 2008-04-29 2013-11-13 法奈科斯公司 基于磺胺异噁唑的组合物用于制备治疗阿茨海默病的药物的应用
NZ589304A (en) * 2008-04-29 2012-03-30 Pharnext Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate
DK2282778T3 (en) * 2008-04-29 2017-05-01 Pharnext NEW THERAPEUTIC APPROACHES TO TREAT ALZHEIMER'S DISEASE AND RELATED DISEASES THROUGH A MODULATION OF ANGIOGENIC
US9399032B2 (en) * 2009-05-14 2016-07-26 The General Hospital Corporation Methods and compositions for treating degenerative and ischemic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090298852A1 (en) * 2005-03-23 2009-12-03 Gernot Francas Pellet-form slow-release preparation for vertigo

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Briani et. al. (European journal of neurology (2004) 11:709-710). *
Toll et. al. (Lupus (1998) 7:363-366). *

Also Published As

Publication number Publication date
JP6426663B2 (ja) 2018-11-21
DE102010062810A1 (de) 2012-03-08
JP6084924B2 (ja) 2017-02-22
EP2614060A2 (de) 2013-07-17
CA2870626C (en) 2018-08-14
RU2016118021A3 (de) 2020-02-26
EP2614060B1 (de) 2016-08-31
EP2693216B1 (de) 2018-09-12
MX357521B (es) 2018-07-12
ES2605705T3 (es) 2017-03-15
WO2012031941A2 (de) 2012-03-15
CN103237802A (zh) 2013-08-07
PL2693216T3 (pl) 2019-04-30
JP2017019776A (ja) 2017-01-26
DK2614060T3 (da) 2017-01-02
MX2013002612A (es) 2013-08-01
CN103237802B (zh) 2017-06-09
EP3097914A3 (de) 2016-12-28
US20150024418A1 (en) 2015-01-22
EP3097914A2 (de) 2016-11-30
CA2811454C (en) 2017-03-28
ES2701453T3 (es) 2019-02-22
PL2614060T3 (pl) 2017-05-31
US20150374711A1 (en) 2015-12-31
CA2870626A1 (en) 2012-03-15
DE102011053114A1 (de) 2012-03-08
RU2587154C2 (ru) 2016-06-20
CA2811454A1 (en) 2012-03-15
DK2693216T3 (en) 2019-01-14
DE102010062810B4 (de) 2014-03-13
RU2016118021A (ru) 2018-11-01
RU2013110018A (ru) 2014-10-20
CN106243060A (zh) 2016-12-21
BR112013005472A2 (pt) 2020-11-10
JP2013537881A (ja) 2013-10-07
EP2693216A1 (de) 2014-02-05
US9370523B2 (en) 2016-06-21
WO2012031941A3 (de) 2012-09-20

Similar Documents

Publication Publication Date Title
Chen et al. Aggregation of the nucleic acid–binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation
Krohn et al. Cerebral amyloid-β proteostasis is regulated by the membrane transport protein ABCC1 in mice
Greotti et al. Familial Alzheimer’s disease-linked presenilin mutants and intracellular Ca2+ handling: A single-organelle, FRET-based analysis
US6008221A (en) Method for treating Alzheimer's disease with folic acid
US8278298B2 (en) Inhibition of tau-tau-association
US7666886B2 (en) Compounds and methods for the diagnosis and treatment of amyloid associated diseases
US9551721B2 (en) Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
JP2002515437A (ja) アミロイド症を調整するためのイオン透過担体を含む組成
JP6417324B2 (ja) τリン酸化を阻害する方法
US9370523B2 (en) Method for diagnosing or prediagnosing a beta-amyloidopathy or an alpha-synucleopathy
JP2018517402A (ja) ホスファターゼ選択的および非選択的なホスファターゼ阻害剤を選択するための方法
Kuret Detection and reduction of neurofibrillary lesions
JP2008530999A (ja) ミクログリア促進アミロイド形成のアッセイ
US20130035302A1 (en) Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid
WO2024061658A1 (en) Thiazole derivatives as tau aggregation inhibitors
Best et al. Quantitative measurement of changes in Aβ40 in the rat brain and CSF following treatment with the γ-secretase inhibitor, N2-[(2S)-2-(3, 5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5Hdibenzo [b, d] azepin-7-yl]-L-alaninamide (LY-411575)
WO2013020909A1 (en) Materials and methods for the treatment of tauopathies
Nijholt The unfolded protein response: a common pathomechanism in tauopathies
Day Autophagy: From Membrane Movement to Nuclear Regulation.

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMMUNGENETICS AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PAHNKE, JENS;REEL/FRAME:030150/0654

Effective date: 20130319

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION